GentaGel
Slow-release Antibiotic Treatment
StartupGentaGel is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2021. Slow-release Antibiotic Treatment. GentaGel was founded by Abraham Domb. The company has 1-10 employees. Core technologies: Materials & Substances, Polymers.
The company follows a B2C business model. Product stage: Clinical Trial.
- StagePre-Funding
- ProductClinical Trial
- ModelB2C
- Employees1-10
- HQJerusalem
- Last RoundUndisclosed
Abraham DombCo-founder
What does GentaGel do?
GentaGel develops a local slow-release antibiotic treatment, which is injected and continuously releases antibiotics for up to 60 days. The antibiotic is not detectable in circulation but achieves sufficient therapeutic concentrations in the administered area. GentaGel provides an effective antibiotic treatment while avoiding systemic side-effects and expensive cost-of-care. The company is based on a ground-breaking drug delivery technology invented by Prof. Domb, for the in-situ sustained release of antibiotics for the treatment and prevention of surgical site infections.
Who founded GentaGel?
GentaGel was founded in 2021 by Abraham Domb (Co-founder).
What sector is GentaGel in?
GentaGel operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Materials & Substances, Polymers. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Healthcare, Providers, Medical Devices Industry, Medical Products.
Where is GentaGel located?
GentaGel is based in HaKalanit St 10, Jerusalem, Israel.